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Pituitary macroadenoma resulting from primary 
hypothyroidism; a 16-year-old girl 
 
 
Abstract 
Background: Primary hypothyroidism is a common medical condition. It can lead to 
pituitary adenoma which is usually asymptomatic, but it can also lead to symptomatic 
macroadenomas which are hard to diagnose due to different clinical presentations. 
Case presentation: A 16-year-old girl presented for endocrinology consultation prior to 
neurosurgical operation. She had galactorrhea which was accompanied by vertigo & low 
grade blurred vision without a headache and was diagnosed with pituitary macroadenoma 
and was planned for a surgery. She had TSH level of more than 100 mU/L, free thyroxine 
of 1.9 pmol/L. Her thyroid peroxidase (TPO) antibody level was 13.3 IU/mL, insulin 
growth factor-1 392 µ/l and serum prolactin level 42 ng/ml. During physical exam and 
with the laboratory findings, we suspected for a primary hypothyroidism as the leading 
cause of pituitary macroadenoma. As the result, we cancel the surgery and start 
levothyroxine therapy 100µg daily for her. In the follow-up it revealed that our diagnosis 
was correct and she went into remission with pituitary gland shrinking and decreasing TSH 
and prolactin levels. 
Conclusion: It is important to understand the different presentation of primary 
hypothyroidism to decrease the unnecessary risk of maltreatment in patients. 
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Primary hypothyroidism or thyroid hormone deficiency due to the abnormality in the 
thyroid gland is the most common endocrine disease. The prevalence of hypothyroidism in 
the general population ranges from 3.8%–4.6 (1). Symptoms may be vague, misleading 
and thus, delay the diagnosis, which can be made in unusual circumstances. Thyrotrophic 
cell hyperplasia has been described in longstanding hypothyroidism and may mimic the 
appearance of a pituitary macroadenoma (2, 3). Pituitary hyperplasia is an enlargement of 
the pituitary gland due to a reversible increase in the number and/or hyperplasia in one or 
more hormone-producing cell types. It can occur as a normal response to physiological 
stimulation during infancy, pregnancy, and lactation, or as a pathological condition (2). 
Pituitary enlargement in primary hypothyroidism is mainly asymptomatic (4). We are 
presenting a case of primary hypothyroidism which led to symptomatic pituitary 
enlargement and the patient was at risk of the unnecessary neurosurgical operation. 
 
 
Case presentation 
A 16-year-old female presented to Endocrinology clinic for pre-surgical consultation. 
She was a candidate for neurosurgical operation due to hypophyseal macroadenoma. 
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Her problems began 7 months ago with a chief complaint 
of galactorrhea which was accompanied by vertigo and low 
grade blurred vision without any headache. She had regular 
menstruations and had her first menstruation when she was 
12 years old. She had no significant family history, she did 
not use any drugs with normal habitual history. She was 
married but she did not have children. In her primary visit, 
laboratory tests were asked for her and the following 
measures were reported: CBC ,ESR showed normal 
measures , thyroid stimulation hormone (TSH) level of more 
than 100 mU/L (reference range 0.350–4.94), free thyroxine 
(FT4) of 2.4  pmol/L (9.0–19.0 ), serum cortisol level was 14 
µ g/dl (3-20 µg/dl), insulin growth factor-1 (IGF-1) 235 µ/l 
(84–100 µ/l) and serum prolactin level 31 ng/ml (4-23 
ng/mL). Based on the above laboratory investigation, she 
was referred for a neurosurgical consultation due to her 
vertigo. Neurosurgeon asked for a brain MRI which showed 
the following measures:  
Pituitary magnetic resonance imaging (MRI) revealed a 
17×12×11 mm homogeneous pituitary mass with upward 
convexity, discreetly hyper-intense on a T1 weighted image 
and hyper-intense on a T2 weighted image too (figure 1). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 (A: left, B: Right): First MRI before treatment 
showed a 17×12×11 mm pituitary mass  
 A neurosurgical operation was decided for the patient 
and she referred for endocrinology consultation. In 
endocrinology clinic (Loghman Hakim Hospital), physical 
examination revealed a well-developed female. Her weight 
was 54 kg, height 157cm and her body mass index was 22. 
Her vital signs were stable. She had normal secondary sexual 
characteristics; in thyroid examination, we found a diffuse 
goiter with 30-gram weight and firm consistency and 
induced galactorrhea was seen, too. 
New necessary laboratory tests considering previous 
laboratory tests were requested for her in our endocrinology 
clinic which showed the following measures:  
Thyroid stimulation hormone (TSH) level of more than 
100 mU/L (reference range 0.350–4.94), free thyroxine 
(FT4) of 1.9 pmol/L (9.0–19.0). Her thyroid peroxidase 
(TPO) antibody level was 13.3 IU/mL (less than 35 IU/mL, 
serum cortisol level was 15.8 µg/dl (3-20 µg/dl), insulin 
growth factor-1 (IGF-1) 392 µ/l (84–100 µ/l) and serum 
prolactin level 42 ng/ml (4-23 ng/ml. She had normal 
perimetry (visual field test) although with blurred vision. 
 
 
Discussion 
The main complaint of our patient was a galactorrhea 
which was due to high prolactin level. Fatigue and vertigo 
due to pituitary macro-adenoma led to performing cerebral 
imaging. The clinical features of hypothyroidism were 
unmarked in this case which leads to misdiagnosis in the first 
step. Primary hypothyroidism can result in reactive 
enlargement of the pituitary gland which is indistinguishable 
from primary pituitary lesions on magnetic resonance 
imaging (MRI) and these results from the loss of thyroxine 
feedback inhibition and subsequent over-production of 
thyroid-stimulating hormone (5). It is important to 
differentiate between reactive enlargement of the pituitary 
gland due to longstanding hypothyroidism from non-function 
pituitary macroadenoma that is usually presented with 
hypopituitarism and hyperprolactinemia due to stalk effect. 
There is a low level of FT4 and low TSH. In non-function 
pituitary macroadenoma, not any high TSH is compatible 
with our case (6) and so is lymphocytic hypophysitis. An 
unusual postpartum lymphocytic inflammatory pituitary 
lesion can be associated with a mass lesion. Over half 
patients with lymphatic hypophysitis present with headache, 
visual field impairment and hyperprolactinemia. 56% of 
patients have secondary hypoadrenalism, followed in 
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frequency by hypothyroidism, hypogonadism, and GH 
deficiency. The pituitary stalk may thicken especially when 
diabetes insipidus is present. Erythrocyte sedimentation rate 
(ESR) is often elevated Although in this case is not fulfilled 
criteria of lymphocytic hypophysitis, but maybe 
concomitantly both diseases are not known (7) and finally 
with regard to TSH –producing adenoma (8) that our patient 
had no symptoms or signs of hyperthyroidism such as 
palpitation, tremor, and there was no elevation in FT4 and 
FT3 in lab tests that was compatible with TSH -producing 
adenoma. 
Based on the clinical, laboratory and imaging findings, 
we considered a diagnosis of primary hypothyroidism 
complicated by compensatory pituitary hyperplasia. With 
this diagnosis, we decided to cancel surgery and started the 
patient on levothyroxine substitution therapy gradually 
increasing to 100 µg daily, after 2 months follow-up, his 
TSH level of 0.6 mU/L (reference range 0.350–4.94), FT4 
6.7 pmol/L (9.0–19.0) and serum prolactin level of 16 ng/ml 
(4-23 ng/mL) were in normal reference ranges; galactorrhea 
and blurred vision disappeared. Follow-up MRI study of 4 
months later documented "a small (2mm) pituitary over 
shape lesion at left pituitary lobe " and 1 year later, no 
pituitary mass was reported (figure 2). 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (A: left, B: right): MRI (4 months after treatment) 
showed a small (2 mm) lesion at left pituitary lobe 
Considering the significant decrease in tumor size, the 
diagnosis was made as thyrotrophic hyperplasia in the 
pattern of primary hypothyroidism and the patient did not 
need neurosurgical treatment and answered well to 
levothyroxine, according to our case, Sarliset al. reported a 
dramatic shrinkage of a pituitary mass in a case of primary 
hypothyroidism after only one week of acute thyroid 
hormone therapy which make us more comfortable with our 
decision (9) also, Amal Moumenet al. reported a similar case 
of pituitary macroadenoma due to primary hypothyroidism 
that responded perfectly to levothyroxine therapy with great 
shrinkage of pituitary mass after 4 months of treatment 
which is exactly the same as our case (10). 
In conclusion, based on the results of this case, although 
there was enough knowledge of the patient's hormonal 
profile, the pituitary mass was first reported as a 
macroadenoma. After documenting the primary 
hypothyroidism, we considered the diagnosis of reactive 
pituitary hyperplasia, which was definitively confirmed by 
the regression of the pituitary mass on the control MRI after 
thyroxine therapy allowing us to avoid an unnecessary 
surgery. 
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